Media headlines about CoLucid Pharmaceuticals (NASDAQ:CLCD) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CoLucid Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.3582851133475 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/22/colucid-pharmaceuticals-clcd-earns-daily-news-impact-score-of-0-16.html.
About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.